Dr. Schwartz's research focus is on Hodgkin disease, osteosarcoma and late effects of childhood cancer therapy. She developed ABVE-PC, the standard U.S. treatment for childhood Hodgkin disease. As Chair of Children's Oncology Group (COG) Hodgkin trials, she evaluates early treatment response as a proxy for tumor and host biology. Her studies of late effects focus on fatigue, and cardiac and cognitive toxicity in cancer survivors. She studies drug resistance, drug intensification, and immunomodulation of osteosarcoma.

Research Description

Research efforts focus on the development of novel therapeutics that target specific mechanisms of cancer through understanding of drug resistance and novel targets, particularly in Hodgkin disease and Osteosarcoma. In addition, Dr. Schwartz studies the long-term consequences of therapy, particularly cardiomyopathy after anthracycline therapy, movement restriction and fatigue, and executive dysfunction after leukemia therapy. Her goal is to mitigate effects for survivors and to use the understanding of the pathogenesis of late effects to improve new treatment regimens for newly diagnosed patients.

Awards

Paul C. Gaffney Lectureship, Children's Hospital of Pittsburgh, 1999
National Institutes of Health Public Health Service Training Grant (Johns Hopkins Oncology Center), 1983-1984
American Cancer Society Clinical Fellowship, 1983-1984
Sigma Xi, 1979
National Merit Finalist, 1971

Affiliations

EDITORIAL BOARDS

Journal of Clinical Oncology, 1997-1999, 2003-present
Pediatric Blood & Cancer, 2004-present


MANUSCRIPT REVIEWER

Cancer, Journal of Clinical Oncology, American Journal of Pediatric Hematology/Oncology, International Journal of Radiation Oncology and Biological Physics, New England Journal of Medicine, Journal of the American Medical Association, Archives of Pediatric & Adolescent Medicine, Journal National Cancer Institute, International Journal of Pediatric Hematology/Oncology, Mayo Clinic Proceedings, Pediatric Blood & Cancer, Annals of Oncology


ADVISORY COMMITTEES

National Cancer Institute (NCI): National Institutes of Health (NIH) Special Emphasis Panel/Initial Review Group CONC, 2004, 2005
PDQ Pediatric Cancer treatment Advisory Board, 2002-present
Ad-hoc review Committee Member: NCI-E Review Panel—Children's Cancer Survivor Study, 12/1998, 8/1999
Ad-hoc review Committee Member: NCI-E Review Panel—Intergroup Rhabdomyosarcoma Study—Late Effects Program, 4/1999
PO1 Site reviewer: NCI-D City of Hope, 11/1999.
Ad-hoc review Committee Member: NCI-H Review Panel—Site Visit of Children's Cancer Group, June 1998
National Cancer Institute/Cancer Therapy Evaluation Program (NCI/CTEP) Developmental Steering Committee for Late Effects Toxicity Criteria: Pediatric Representative

Novel Approaches to Neuroblastoma Therapy (NANT)
Chair, Data Safety Monitoring Board, 2002-present

Childhood Cancer Survivor Study (CCSS)
Scientific Advisory Board, 2004-present

National Cancer Policy Board—Institute of Medicine
Pediatric Survivorship Presentation, 2002

American Society of Clinical Oncology (ASCO):
Expert Panel on Long-Term Medical Care for Adult Cancer Survivors, 2005-present
Patients Living With Cancer Advisory Board (Hodgkin's disease), 2003-present


MEMBERSHIP IN SOCIETIES

1989-present American Society of Clinical Oncology
Publications Committee (1999-2001)
CME Committee (2005-present)
1988-present American Society of Pediatric Hematology-Oncology
Program Committee Member (1999-2002)
2003-present American Society of Hematology
1990-1994 American Cancer Society, New York State
Upstate New York Pediatric Oncology Group
1986-1988 Children's Study Cancer Group
Recurrent Lymphoma Committee
1989-2000 Pediatric Oncology Group
Principal Investigator: University of Rochester (1992-1994)
Johns Hopkins (1994-2000)
Full Member (1992-2000)
Associate Member (1989-1992)
Chair, Pediatric Oncology Group (POG) Hodgkin's Committee (1999-2000)
Co-Chair, Hodgkin's Transition Committee (1999-2000)
Hodgkin's Disease Committee Member (1989-2000)
Sarcoma Committee Member (1994-present)
Sarcoma Intergroup/Transition Committee (1997-2000) Osteosarcoma subcommittee (1992-2000)
Bone Tumor Biology subcommittee (1997-2000)
Late Effects Committee (1990-1992)
Cancer Control Committee (1993-1994)
Anthracycline Subcommittee (1991-1995)

2000-present Children's Oncology Group (COG)
Principal Investigator, Johns Hopkins (2000–2005)
Principal Investigator, Rhode Island Hospital (2006-present)
Full Member (2000-present)
Chair, COG Hodgkin Disease Committee (2000-present)
Scientific Chairs Committee (2000-present)
COG Bone Tumor Committee (2000-present)
Osteosarcoma Biology Committee (2000-present)
Developmental Therapeutics Committee (2000-present)
COG Voting Body (2000-present)
COG Voting Body Steering Committee (2000-2003)
COG Adolescent/Young Adult Steering Committee (2002-2004)
Hodgkin Disease Sub-Committee (2002-present)
Survivorship Transition Sub-Committee (2003-present)
Steering Committee (2003-present)

1992-1999 Women in Cancer Research

1995-1999 National Cancer Center Network (NCCN)
Pediatric Committee
Osteosarcoma Subcommittee

Funded Research

GRANTS

Current:

National Institutes of Health/National Cancer Institute Request For Application (NIH/NCI RFA): Survivorship
Hodgkin Disease Survivors: Outcomes of Modern Therapy
6/2004-6/2008, $410,000
Principal Investigator: D. Friedman DC
Principal Investigator (Brown): C. Schwartz (Study Vice Chair) (5%)

NIH/NCI
Children's Oncology Group (28% Total Effort)
1/01/03-12/31/07
Hodgkin's Disease, Committee Chair (18%)
Principal Investigator (Rhode Island Hospital/Brown University) (10%)

NIH/NCI Specialized Programs of Research Excellence (SPORE) in Lymphoma (Ambinder)
Project 1 EBV and Hodgkin's Disease DC.
7/01/2002-6/30/2007, $387,323 (5% Support)
Principal Investigator (Clinical): Project 1

Previous:

Cytogen—Phase I: Samarium-153 for recurrent or metastatic osteosarcoma
2004-2005
Principal Investigator: Cindy L. Schwartz, MD (15% support)

NIH/NCI
Children's Oncology Group
1/01/2003-12/31/2007
Principal Investigator at Johns Hopkins (10% Effort)

NIH/JHH Center in Complementary and Alternative Medicine
RFA: Developmental and Feasibility Studies in the Clinical and Basic Sciences
Movement Restriction and Fatigue in Cancer Survivors
12/01/2002-11/30/2003 DC: $150,000
Principal Investigator: Cindy L. Schwartz, MD (7.5 % Support)

NIH/NCI/2 U10 CA 288 76
Pediatric Oncology Group U10 Award (Johns Hopkins)
07/01/1980-2/28/2003 DC: $202,701/yr
Principal Investigator (Hopkins): Cindy L. Schwartz, MD (18% Support)

NIH/NCI/2 U10 CA 288 76 17
Pediatric Oncology Group
Hodgkin's Disease Committee Chair Funding
1/1/2000-12/31/2002 DC: $10,807
Chair: Cindy L. Schwartz, MD (7% Support)

5ROL HD35528: Behavioral Medicine Approaches to Pediatric Acute Pain
4/1/1998-3/31/2001
Principal Investigator: Keith Slifer, PhD
Pediatric Oncology Co-Investigator: Cindy L. Schwartz, MD (5% Support)

NIH/NCI/3 P30 CA-06973-35S1
Evaluation of Risk for Myocardial Ischemia in Survivors of Hodgkin's Disease Treated with Mediastinal Radiation
5/1/1997-4/30/1999 DC: $292,870
Principal Investigator: Cindy L. Schwartz, MD (20% Support)

NIH P30 CA06973—Cancer Center Support Grant (NIH CORE)
Supplement Developmental Funds Proposal
Clinical Investigation of MDR-1 and Late Effects in Childhood Cancer
5/1/1993-4/30/1996 DC: $50,000
Principal Investigator: Cindy Schwartz, MD

NIH/NCI/5 PO1 CA-34183-11
The Biology and Treatment of Human Leukemia and Lymphoma
8/1/1983-12/31/1994 DC: $16,347 (UR '94)
Principal Investigator: Stephen Sallan, MD (DFCI)
Principal Investigator (University of Rochester 1993-1994): Cindy Schwartz, MD

Agreement #0600-370-C352JHPX
Pediatric Oncology Group Phase I grant at Johns Hopkins 07/01/1999-6/30/2002 Per patient
Principal Investigator (Hopkins): Cindy L. Schwartz, MD (1% Support)

Cancer Action
The Use of Cyclosporin-A to Overcome Multiple Drug Resistance
7/1/1992-6/30/1994 DC: $4,500
Principal Investigator: Cindy L. Schwartz, MD

IN-18-31 American Cancer Society Institutional Award
MRI assessment of Marrow Response to ALL Therapy
1/1/1989-12/31/1989 DC: $7,200
Principal Investigator: Cindy L. Schwartz, MD

Merck: MK-0091 (Caspofungin) Pediatric Pharmacokinetic Study
2001-2002 Per patient reimbursement
Principal Investigator (Hopkins): Cindy L. Schwartz

Berlix—Phase I: Samarium-153 for recurrent or metastatic osteosarcoma
2000-2002 $22,500
Principal Investigator: Cindy L. Schwartz, MD (5% support)

Fujisawa—Phase I/II: Study to Determine the Safety and Pharmacokinetics of FK463 in Febrile Neutropenic Pediatric Patients
1999-2001 Per patient reimbursement
Principal Investigator (Hopkins): Cindy L. Schwartz, MD (1.5% support)

Aronex—Prospectively Randomized Double Blind Comparative Multi-center Study to Evaluate Efficacy and Safety of Nyotran vs. Amphotericin B for Empiric Antifungal Treatment in Neutropenic Patients.
4/8/1999-2000 Per patient reimbursement
Principal Investigator (Hopkins): Cindy L. Schwartz, MD

Pfizer—A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients with Persistent Fever and Neutropenia
1999 Per patient reimbursement
Principal Investigator (Hopkins): Cindy L. Schwartz, MD

Pfizer—A Randomized, Double-Blind, Open Label, Trial of AmBisome (Liposomal Amphotericin B) versus Amphotericin B in the Empiric Treatment of the Febrile Neutropenic Patient
12/1/1994-12/31/1996 Per patient reimbursement
Principal Investigator (Hopkins): Cindy L. Schwartz, MD

View My Full Publication List in pdf format